By exploring the data produced, we discovered several putative novel broad cancer and cancer-specific genes and validated two of them: TGOLN2, a putative novel broad cancer tumour suppressor and EFTUD2, a new putative oncogene in Multiple Myeloma. Here, EFTUD2 is linked to plasma cell myeloma.